Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Adoptive transfer of third-party mesenchymal stromal cells (MSCs) has emerged as a promising tool for the treatment of steroid-refractory graft-versus-host disease (GVHD). Despite numerous in vitro studies and preclinical models, little is known about their effects on the patients' immune system. We assessed immune alterations in the T-cell, B-cell, natural killer cell, dendritic cell, and monocytic compartments of steroid-refractory GVHD patients 30, 90, and 180 days after MSC (n = 6) or placebo (n = 5) infusion, respectively. Infused MSCs were bioactive as suggested by the significant reduction in epithelial cell death, which represents a biomarker for acute GVHD. There were several indications that MSCs shift the patients' immune system toward a more tolerogenic profile. Most importantly, infusion of MSCs was associated with increased levels of regulatory (forkhead box P3 (FOXP3)+ and interleukin (IL)-10+) T-cells, reduced pro-inflammatory IL-17+ T(Th17)-cells, and skewing toward type-2 T-helper cell responses. Furthermore, IL-2, which has been recently shown to exert a positive immune modulating effect in GVHD patients, was higher in the MSC patients at all evaluated time points during 6 months after MSC-infusion. Overall, our findings will contribute to the refinement of monitoring tools, for assessing MSC treatment-efficacy and increase our understanding regarding the MSCs' in vivo effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
A function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Th17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
Yang, X.-P., Ghoreschi, K., Steward-Tharp, S. M., Rodriguez-Canales, J., Zhu, J., Grainger, J. R., Hirahara, K., Sun, H.-W., Wei, L., Vahedi, G., et al. (2011) · Nature Immunology · doi:10.1038/ni.1995 · Cited by 583
Cited by
de Witte, S. F. H., Luk, F., Sierra Parraga, J. M., Gargesha, M., Merino, A., Korevaar, S. S., Shankar, A. S., O'Flynn, L., Elliman, S. J., Roy, D., et al. (2018) · Stem Cells · doi:10.1002/stem.2779 · Cited by 504
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy
Krampera, M., & Le Blanc, K. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.006 · Cited by 260
Self-citationCruz, F. F., Borg, Z. D., Goodwin, M., Sokocevic, D., Wagner, D., McKenna, D. H., Rocco, P. R. M., & Weiss, D. J. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0268 · Cited by 84
Lu, W., Xu, J., Dong, S., Xie, G., Yang, S., Huangfu, X., Li, X., Zhang, Y., Shen, P., Yan, Z., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0132 · Cited by 25
Metadata
- Authors
- Jitschin, R., Mougiakakos, D., Von Bahr, L., Völkl, S., Moll, G., Ringden, O., Kiessling, R., Linder, S., & Le Blanc, K.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-01
- Volume
- 31
- Issue
- 8
- Pages
- 1715-1725
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W1518523639
- Cited by
- 80
- References
- 4
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.